Patents by Inventor G. Leslie Burnett

G. Leslie Burnett has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RAS INHIBITORS
    Publication number: 20230374035
    Abstract: The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
    Type: Application
    Filed: February 6, 2023
    Publication date: November 23, 2023
    Inventors: Elena S. KOLTUN, James CREGG, Naing AAY, Andreas BUCKL, Adrian L. GILL, James AGGEN, G. Leslie BURNETT, Jennifer PITZEN, Daniel M. WHALEN, John E. KNOX, Yang LIU
  • BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF
    Publication number: 20230365605
    Abstract: The present disclosure is directed to modulators of SOS1 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.
    Type: Application
    Filed: October 11, 2022
    Publication date: November 16, 2023
    Inventors: Adrian L. Gill, Andreas Buckl, Elena S. Koltun, Naing Aay, Arlyn A. Tambo-ong, Severin Thompson, Micah James Gliedt, John E. Knox, James Cregg, Anne V. Edwards, Yang Liu, G. Leslie Burnett
  • RAS INHIBITORS
    Publication number: 20230303591
    Abstract: The invention features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
    Type: Application
    Filed: October 7, 2022
    Publication date: September 28, 2023
    Inventors: Andreas Buckl, G. Leslie Burnett, James Cregg, Anne V. Edwards, Adrian L. Gill, John E. Knox, Elena S. Koltun, Yang Liu, Christopher Semko
  • Ras inhibitors
    Patent number: 11739074
    Abstract: The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
    Type: Grant
    Filed: November 4, 2020
    Date of Patent: August 29, 2023
    Assignee: Revolution Medicines, Inc.
    Inventors: James Aggen, G. Leslie Burnett, Jennifer Pitzen, Adrian L. Gill, Elena S. Koltun, James Cregg, Andreas Buckl, Anne V. Edwards, John E. Knox
  • RAS INHIBITORS
    Publication number: 20230234929
    Abstract: The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
    Type: Application
    Filed: January 30, 2023
    Publication date: July 27, 2023
    Inventors: Elena S. KOLTUN, James Cregg, Adrian L. Gill, James Aggen, G. Leslie Burnett, Jennifer Pitzen, Andreas Buckl, John E. Knox, Yang Liu
  • RAS INHIBITORS
    Publication number: 20230226186
    Abstract: The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
    Type: Application
    Filed: March 23, 2023
    Publication date: July 20, 2023
    Inventors: Naing AAY, G. Leslie BURNETT, James CREGG, Adrian L. GILL, John E. KNOX, Elena S. KOLTUN, Yang LIU, Andreas BUCKL, Bianca Jennifer LEE, David E. WILDES, Meghan A. RICE, Mallika SINGH
  • Ras inhibitors
    Patent number: 11690915
    Abstract: The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
    Type: Grant
    Filed: September 15, 2021
    Date of Patent: July 4, 2023
    Assignee: Revolution Medicines, Inc.
    Inventors: Naing Aay, G. Leslie Burnett, James Cregg, Adrian L. Gill, John E. Knox, Elena S. Koltun, Yang Liu, Andreas Buckl, Bianca Jennifer Lee, David E. Wildes, Meghan A. Rice, Mallika Singh
  • C26-linked rapamycin analogs as mTOR inhibitors
    Patent number: 11685749
    Abstract: The present disclosure relates to mTOR inhibitors. Specifically, the embodiments are directed to compounds and compositions inhibiting mTOR, methods of treating diseases mediated by mTOR, and methods of synthesizing these compounds.
    Type: Grant
    Filed: October 30, 2020
    Date of Patent: June 27, 2023
    Assignee: REVOLUTION MEDICINES, INC.
    Inventors: Christopher Michael Semko, Gang Wang, G. Leslie Burnett, James Bradley Aggen, Gert Kiss, James Joseph Cregg, Micah James Evans Gliedt, Jennifer Pitzen, Julie Chu-Li Lee, Walter Won, Arun P. Thottumkara, Adrian Liam Gill
  • RAS INHIBITORS
    Publication number: 20230106174
    Abstract: The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
    Type: Application
    Filed: May 5, 2022
    Publication date: April 6, 2023
    Inventors: Elena S. KOLTUN, James CREGG, Adrian L. GILL, John E. KNOX, Yang LIU, G. Leslie BURNETT
  • COVALENT RAS INHIBITORS AND USES THEREOF
    Publication number: 20230100838
    Abstract: The disclosure features compounds, or pharmaceutically acceptable salts thereof, alone and in combination with other therapeutic agents, pharmaceutical compositions, and protein conjugates thereof, capable of modulating biological processes including Ras, and their uses in the treatment of cancers.
    Type: Application
    Filed: May 26, 2022
    Publication date: March 30, 2023
    Inventors: Jennifer PITZEN, James AGGEN, G. Leslie BURNETT, Adrian L. GILL, Christopher SEMKO, Anne V. EDWARDS, Micah James GLIEDT, Gert KISS, Ashutosh JOGALEKAR, John E. KNOX, Andreas BUCKL, Elena S. KOLTUN
  • RAPAMYCIN ANALOGS AS MTOR INHIBITORS
    Publication number: 20230093861
    Abstract: The present disclosure relates to mTOR inhibitors. Specifically, the embodiments are directed to compounds and compositions inhibiting mTOR, methods of treating diseases mediated by mTOR, and methods of synthesizing these compounds.
    Type: Application
    Filed: March 11, 2022
    Publication date: March 30, 2023
    Inventors: James Bradley AGGEN, Arun P. THOTTUMKARA, G. Leslie BURNETT, Micah James Evans GLIEDT, Gert KISS, Walter WON, Julie Chu-Li LEE, Adrian Liam GILL, Christopher SEMKO, Jennifer PITZEN, Gang WANG, Nidhi TIBREWAL
  • C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors
    Publication number: 20230055672
    Abstract: The present disclosure relates to mTOR inhibitors. Specifically, the embodiments are directed to compounds and compositions inhibiting mTOR, methods of treating diseases mediated by mTOR, and methods of synthesizing these compounds.
    Type: Application
    Filed: April 29, 2022
    Publication date: February 23, 2023
    Inventors: Jennifer Pitzen, Micah James Evans Gliedt, G. Leslie Burnett, James Bradley Aggen, Gert Kiss, James Joseph Cregg, Christopher Michael Semko, Walter Won, Gang Wang, Julie Chu-Li Lee, Arun P. Thottumkara, Adrian Liam Gill, Kevin T. Mellem
  • RAS INHIBITORS
    Publication number: 20220396589
    Abstract: The invention features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
    Type: Application
    Filed: May 5, 2022
    Publication date: December 15, 2022
    Inventors: Andreas BUCKL, G. Leslie BURNETT, James CREGG, Anne V. EDWARDS, Adrian L. GILL, John E. KNOX, Elena S. KOLTUN, Jennifer PITZEN, Christopher SEMKO
  • C26-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS
    Publication number: 20220340596
    Abstract: The present disclosure relates to mTOR inhibitors. Specifically, the embodiments are directed to compounds and compositions inhibiting mTOR, methods of treating diseases mediated by mTOR, and methods of synthesizing these compounds.
    Type: Application
    Filed: October 30, 2020
    Publication date: October 27, 2022
    Inventors: Christopher Michael SEMKO, Gang WANG, G. Leslie BURNETT, James Bradley AGGEN, Gert KISS, James Joseph CREGG, Micah James Evans GLIEDT, Jennifer PITZEN, Julie Chu-Li LEE, Walter WON, Arun P. THOTTUMKARA, Adrian Liam GILL
  • C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors
    Patent number: 11364300
    Abstract: The present disclosure relates to mTOR inhibitors. Specifically, the embodiments are directed to compounds and compositions inhibiting mTOR, methods of treating diseases mediated by mTOR, and methods of synthesizing these compounds.
    Type: Grant
    Filed: October 28, 2020
    Date of Patent: June 21, 2022
    Assignee: REVOLUTION MEDICINES, INC.
    Inventors: Jennifer Pitzen, G. Leslie Burnett, James Bradley Aggen
  • RAS INHIBITORS
    Publication number: 20220105185
    Abstract: The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
    Type: Application
    Filed: September 15, 2021
    Publication date: April 7, 2022
    Inventors: Naing AAY, G. Leslie BURNETT, James CREGG, Adrian L. GILL, John E. KNOX, Elena S. KOLTUN, Yang LIU, Andreas BUCKL, Bianca Jennifer LEE, David E. WILDES, Meghan A. RICE, Mallika SINGH
  • Bicyclic heteroaryl compounds and uses thereof
    Patent number: 11168102
    Abstract: The present disclosure is directed to modulators of SOS1 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same. Modulators of SOS1 have the following general structure of the Formula (II), or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein the variables are as defined herein.
    Type: Grant
    Filed: December 23, 2020
    Date of Patent: November 9, 2021
    Assignee: Revolution Medicines, Inc.
    Inventors: Adrian L. Gill, Andreas Buckl, Elena S. Koltun, Naing Aay, Arlyn A. Tambo-ong, Severin Thompson, Micah James Gliedt, John E. Knox, James Cregg, Anne V. Edwards, Yang Liu, G. Leslie Burnett
  • C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors
    Publication number: 20210338824
    Abstract: The present disclosure relates to mTOR inhibitors. Specifically, the embodiments are directed to compounds and compositions inhibiting mTOR, methods of treating diseases mediated by mTOR, and methods of synthesizing these compounds.
    Type: Application
    Filed: October 28, 2020
    Publication date: November 4, 2021
    Inventors: Jennifer Pitzen, Micah James Evans Gliedt, G. Leslie Burnett, James Bradley Aggen, Gert Kiss, James Joseph Cregg, Christopher Michael Semko, Walter Won, Gang Wang, Julie Chu-Li Lee, Arun P. Thottumkara, Adrian Liam Gill, Kevin T. Mellem
  • BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF
    Publication number: 20210139517
    Abstract: The present disclosure is directed to modulators of SOS1 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.
    Type: Application
    Filed: November 5, 2020
    Publication date: May 13, 2021
    Inventors: Adrian L. Gill, Andreas Buckl, Elena S. Koltun, Naing Aay, Arlyn A. Tambo-ong, Severin Thompson, Micah James Gliedt, John E. Knox, James Cregg, Anne V. Edwards, Yang Liu, G. Leslie Burnett
  • RAS INHIBITORS
    Publication number: 20210130369
    Abstract: The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
    Type: Application
    Filed: November 4, 2020
    Publication date: May 6, 2021
    Inventors: Elena S. KOLTUN, James CREGG, Naing AAY, Andreas BUCKL, Adrian L. GILL, James AGGEN, G. Leslie BURNETT, Jennifer PITZEN, Daniel M. WHALEN, John E. KNOX, Yang LIU